Literature DB >> 2318511

Improvement in sensitivity of enzyme-linked immunosorbent assay for tumour necrosis factor.

P J McLaughlin1, N J Elwood, L T Ramadi, M R Pica, I F McKenzie.   

Abstract

Various protocols were used in the development of enzyme-linked immunosorbent assays (ELISA) to improve the sensitivity and range of detection of human tumour necrosis factor-alpha (TNF-alpha). ELISA can provide a specific, sensitive and rapid method for detection of TNF-alpha in patient's sera, and it is important that the assay used should be sufficiently sensitive to detect low levels of TNF-alpha. The double sandwich ELISA proved to be the most sensitive, detecting less than 0.080 ng/mL TNF. Of eight different protocols, one assay using a purified monoclonal antibody to human TNF-alpha and rabbit polyclonal anti-TNF-alpha antibody had the greatest sensitivity and range of detection. The study illustrates methods for the development of sensitive immunoassays which may have applications in many assay systems.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2318511     DOI: 10.1038/icb.1990.7

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  4 in total

1.  Tumour necrosis factor alpha is elevated in serum and cerebrospinal fluid in multiple sclerosis and inflammatory neuropathies.

Authors:  M Rentzos; C Nikolaou; A Rombos; K Voumvourakis; I Segditsa; C Papageorgiou
Journal:  J Neurol       Date:  1996-02       Impact factor: 4.849

2.  IL-4 suppresses IL-1 beta, TNF-alpha and PGE2 production by human peritoneal macrophages.

Authors:  P H Hart; R L Cooper; J J Finlay-Jones
Journal:  Immunology       Date:  1991-03       Impact factor: 7.397

3.  Soluble mediators and cytokines produced by human CD3- leucocyte clones from decidualized endometrium.

Authors:  G Deniz; S E Christmas; P M Johnson
Journal:  Immunology       Date:  1996-01       Impact factor: 7.397

4.  Endothelial cell activation by tumour necrosis factor-alpha (TNF-alpha) and the development of pre-eclampsia.

Authors:  J W Meekins; P J McLaughlin; D C West; I R McFadyen; P M Johnson
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.